Cargando…

Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal(®) Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil

BACKGROUND: Aripiprazole lauroxil (AL), a long-acting injectable antipsychotic for the treatment of schizophrenia in adults, can be started with either 21 days of daily oral aripiprazole supplementation or a 1-day initiation regimen consisting of a single injection of a NanoCrystal(®) Dispersion for...

Descripción completa

Detalles Bibliográficos
Autores principales: Hard, Marjie L., Wehr, Angela, von Moltke, Lisa, Du, Yangchun, Farwick, Sarah, Walling, David P., Sonnenberg, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607563/
https://www.ncbi.nlm.nih.gov/pubmed/31308935
http://dx.doi.org/10.1177/2045125319859964
_version_ 1783432117364981760
author Hard, Marjie L.
Wehr, Angela
von Moltke, Lisa
Du, Yangchun
Farwick, Sarah
Walling, David P.
Sonnenberg, John
author_facet Hard, Marjie L.
Wehr, Angela
von Moltke, Lisa
Du, Yangchun
Farwick, Sarah
Walling, David P.
Sonnenberg, John
author_sort Hard, Marjie L.
collection PubMed
description BACKGROUND: Aripiprazole lauroxil (AL), a long-acting injectable antipsychotic for the treatment of schizophrenia in adults, can be started with either 21 days of daily oral aripiprazole supplementation or a 1-day initiation regimen consisting of a single injection of a NanoCrystal(®) Dispersion formulation of AL (AL(NCD)) and a single dose of 30 mg oral aripiprazole. This phase I study assessed the pharmacokinetics and safety of deltoid versus gluteal AL(NCD) injections. METHODS: Patients with schizophrenia or schizoaffective disorder (N = 47) were randomized 1:1 to receive a single intramuscular dose of AL(NCD) in the deltoid or gluteal muscle. Plasma samples were collected over 85 days to measure AL(NCD) concentration by injection site. Relative aripiprazole bioavailability for deltoid versus gluteal injection was assessed based on area under the curve (AUC(∞) and AUC(last)) and maximum concentration (C(max)) values. Adverse events were monitored throughout the study. RESULTS: Plasma aripiprazole concentrations after a single AL(NCD) injection were comparable between deltoid and gluteal administration. Mean maximum plasma aripiprazole concentrations were 196.1 ng/ml (deltoid) and 175.0 ng/ml (gluteal). Exposure to aripiprazole was similar, with mean AUC(∞) values of 6591 day × ng/ml for deltoid and 6437 day × ng/ml for gluteal. Aripiprazole bioavailability was not significantly different between injection sites. AL(NCD) administration in the deltoid or gluteal muscle was well tolerated, with similar safety profiles at both sites. CONCLUSION: AL(NCD) demonstrated similar exposure and safety profiles between the two administration sites, suggesting that AL(NCD) can be given in either the gluteal or the deltoid muscles as a component of the 1-day initiation regimen for AL.
format Online
Article
Text
id pubmed-6607563
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-66075632019-07-15 Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal(®) Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil Hard, Marjie L. Wehr, Angela von Moltke, Lisa Du, Yangchun Farwick, Sarah Walling, David P. Sonnenberg, John Ther Adv Psychopharmacol Original Research BACKGROUND: Aripiprazole lauroxil (AL), a long-acting injectable antipsychotic for the treatment of schizophrenia in adults, can be started with either 21 days of daily oral aripiprazole supplementation or a 1-day initiation regimen consisting of a single injection of a NanoCrystal(®) Dispersion formulation of AL (AL(NCD)) and a single dose of 30 mg oral aripiprazole. This phase I study assessed the pharmacokinetics and safety of deltoid versus gluteal AL(NCD) injections. METHODS: Patients with schizophrenia or schizoaffective disorder (N = 47) were randomized 1:1 to receive a single intramuscular dose of AL(NCD) in the deltoid or gluteal muscle. Plasma samples were collected over 85 days to measure AL(NCD) concentration by injection site. Relative aripiprazole bioavailability for deltoid versus gluteal injection was assessed based on area under the curve (AUC(∞) and AUC(last)) and maximum concentration (C(max)) values. Adverse events were monitored throughout the study. RESULTS: Plasma aripiprazole concentrations after a single AL(NCD) injection were comparable between deltoid and gluteal administration. Mean maximum plasma aripiprazole concentrations were 196.1 ng/ml (deltoid) and 175.0 ng/ml (gluteal). Exposure to aripiprazole was similar, with mean AUC(∞) values of 6591 day × ng/ml for deltoid and 6437 day × ng/ml for gluteal. Aripiprazole bioavailability was not significantly different between injection sites. AL(NCD) administration in the deltoid or gluteal muscle was well tolerated, with similar safety profiles at both sites. CONCLUSION: AL(NCD) demonstrated similar exposure and safety profiles between the two administration sites, suggesting that AL(NCD) can be given in either the gluteal or the deltoid muscles as a component of the 1-day initiation regimen for AL. SAGE Publications 2019-07-02 /pmc/articles/PMC6607563/ /pubmed/31308935 http://dx.doi.org/10.1177/2045125319859964 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Hard, Marjie L.
Wehr, Angela
von Moltke, Lisa
Du, Yangchun
Farwick, Sarah
Walling, David P.
Sonnenberg, John
Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal(®) Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil
title Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal(®) Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil
title_full Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal(®) Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil
title_fullStr Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal(®) Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil
title_full_unstemmed Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal(®) Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil
title_short Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal(®) Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil
title_sort pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil nanocrystal(®) dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607563/
https://www.ncbi.nlm.nih.gov/pubmed/31308935
http://dx.doi.org/10.1177/2045125319859964
work_keys_str_mv AT hardmarjiel pharmacokineticsandsafetyofdeltoidorglutealinjectionofaripiprazolelauroxilnanocrystaldispersionusedforinitiationofthelongactingantipsychoticaripiprazolelauroxil
AT wehrangela pharmacokineticsandsafetyofdeltoidorglutealinjectionofaripiprazolelauroxilnanocrystaldispersionusedforinitiationofthelongactingantipsychoticaripiprazolelauroxil
AT vonmoltkelisa pharmacokineticsandsafetyofdeltoidorglutealinjectionofaripiprazolelauroxilnanocrystaldispersionusedforinitiationofthelongactingantipsychoticaripiprazolelauroxil
AT duyangchun pharmacokineticsandsafetyofdeltoidorglutealinjectionofaripiprazolelauroxilnanocrystaldispersionusedforinitiationofthelongactingantipsychoticaripiprazolelauroxil
AT farwicksarah pharmacokineticsandsafetyofdeltoidorglutealinjectionofaripiprazolelauroxilnanocrystaldispersionusedforinitiationofthelongactingantipsychoticaripiprazolelauroxil
AT wallingdavidp pharmacokineticsandsafetyofdeltoidorglutealinjectionofaripiprazolelauroxilnanocrystaldispersionusedforinitiationofthelongactingantipsychoticaripiprazolelauroxil
AT sonnenbergjohn pharmacokineticsandsafetyofdeltoidorglutealinjectionofaripiprazolelauroxilnanocrystaldispersionusedforinitiationofthelongactingantipsychoticaripiprazolelauroxil